Key insights
- Revolution Medicines executive Anthony Mancini sold approximately $480,610 in stock under a pre-arranged plan, coinciding with the stock trading near its 52-week high. This insider selling, coupled with a recent earnings miss and indications of overvaluation, suggests potential headwinds for the stock. The company also reported higher than expected SG&A and R&D expenses, further contributing to a bearish outlook.
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, Inc. (NASDAQ:RVMD), recently sold shares of the company’s common stock totaling approximately $480,610. The transactions occurred on May 26, 2026, and were executed under a pre-arranged 10b5-1 trading plan adopted on December 24, 2025.
Mancini sold a total of 3,121 shares of common stock. These sales were conducted in multiple trades at varying prices:
700 shares were sold at a weighted average price of $153.3023 per share, with individual prices ranging from $152.64 to $153.48.
2,000 shares were sold at a weighted average price of $154.0609 per share, with individual prices ranging from $153.65 to $154.51.
421 shares were sold at a weighted average price of $154.8157 per share, with individual prices ranging from $154.70 to $154.95.
Prior to these sales, Mancini acquired 3,121 shares of common stock by exercising stock options at a price of $33.62 per share, totaling approximately $104,928. This acquisition was also part of the 10b5-1 trading plan.
Following these transactions, Anthony Mancini directly holds 54,400 shares of Revolution Medicines common stock. This figure includes 54,400 Restricted Stock Units.The sales occurred as RVMD trades near its 52-week high of $156.25, following a remarkable 305% gain over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. Investors seeking deeper insights can access comprehensive analysis through InvestingPro, including additional ProTips and detailed financial metrics for Revolution Medicines.
In other recent news, Revolution Medicines reported first-quarter 2026 earnings per share of negative $2.29, missing the consensus estimate of negative $1.64. This shortfall was attributed to higher than expected selling, general, and administrative expenses, which exceeded estimates by $46.3 million, and research and development expenses, surpassing expectations by $67.4 million. Bernstein SocGen Group initiated coverage on Revolution Medicines with a Market Perform rating, citing that the value of future portfolio revenue upside is already reflected in the current share price. Truist Securities also initiated coverage, assigning a buy rating and raising the price target from $116.00 to $179.00, emphasizing the potential of daraxonrasib in RAS-mutant cancers. Needham maintained a Buy rating but lowered its price target to $183 due to higher costs. Additionally, Revolution Medicines announced that data from its Phase 1/2 clinical trial of daraxonrasib has been published in The New England Journal of Medicine. The company plans to host a webcast to discuss results from its Phase 3 RASolute 302 clinical trial, which it characterized as positive. These developments underscore the ongoing interest and analysis from various firms regarding Revolution Medicines’ potential in the cancer treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for RVMD plus thousands of other stocks and find your next hidden gem with massive upside.